

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/597,304
				Filing Date	July 19, 2006
				First Named Inventor	John P. Morseman
				Art Unit	1614
				Examiner Name	Jennifer M. Kim
Sheet	1	of	4	Attorney Docket Number	2997-74-PUS

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. 1	Document Number Number-kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee of Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	2002/077317	06/20/02	Das	
	2	2004/0266874	12/30/04	Akimoto et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code <sup>3</sup> ; Number <sup>4</sup> ; Kind Code <sup>5</sup> (if known)	Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	3	CA 2052577	04/02/93	Tisdale et al.		
	4	EP 1275399	01/15/03	Nutricia		
	5	EP 0385859	09/05/90	Ceriani et al.		
	6	EP 1419768	05/19/04	Suntory Ltd.		
	7	WO 01/17524	03/15/01	Das		
	8	WO 01/49282	07/12/01	David et al.		
	9	WO 01/49284	07/12/01	EFA Sciences LLC		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT****Complete if Known**

Application Number	10/597,304
Filing Date	July 19, 2006
First Named Inventor	John P. Morseman
Art Unit	1614
Examiner Name	Jennifer M. Kim
Attorney Docket Number	2997-74-PUS

Sheet

2

of

4

	10	WO 02/02105	01/10/02	Horrobin		
	11	WO 02/096408	12/05/02	Horrobin		
	12	WO 03/013497	02/20/03	Akimoto et al.		(believed to correspond to 2004/0266874 disclosed herein)
	13	WO 02/26936	04/04/02	Thomas et al.		
	14	WO 03/039575	05/15/03	Bertilsson et al.		
	15	WO 03/041701	05/22/03	Kiliaan et al.		
	16	WO 03/063110	07/31/03	Fatemi		
	17	WO 2004/012753	02/12/04	Crede		
	18	WO 2004/050913	06/17/04	Horrobin		
	19	WO 96/37200	11/28/96	Stordy		
	20	WO 96/40106	12/19/96	David et al.		
	21	WO 98/08501	03/05/98	Horrobin		
	22	WO 98/16216	04/23/98	Horrobin		
	23	WO 98/48788	11/05/98	Horrobin		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/597,304
				Filing Date	July 19, 2006
				First Named Inventor	John P. Morseman
				Art Unit	1614
				Examiner Name	Jennifer M. Kim
Sheet	3	of	4	Attorney Docket Number	2997-74-PUS

OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)		
Examiner Initials*	Cite No. <sup>1</sup>	
	24	ALVAREZ-DOLADO et al., "Thyroid Hormone Regulates reelin and dab1 Expression during Brain Development", The Journal of Neuroscience, August 15, 1999, 19(16):6979-6993
	25	COSTA E et al., "Dendritic spine hypoplasticity and downregulation of reelin and GABAergic tone in schizophrenia vulnerability", Neurobiology of Disease, Blackwell Scientific Publications, Oxford, GB, Vol. 8, No. 5, October 1, 2001
	26	COSTA E. et al., "Reelin and Schizophrenia: A Disease at the Interface of the Genome and the Epigenome", Molecular Interventions, February 2002, Vol. 2, Issue 1, pp. 47-57
	27	FATEMI et al., "Altered levels of Feelin and its isoforms in schizophrenia and mood disorders", Neuroreport, October 29, 2001, 12(15):3209-15
	28	GUIDOTTI et al., "Decrease in Reelin and Glutamic Acid Decarboxylase(67) (GAD67) Expression in Schizophrenia and Bipolar Disorder", Arch. Gen. Psychiatry, 2000, 57:1061-1069
	29	HAAS et al., "Role for Feelin in the Development of Granule Cell Dispersion in Temporal Lobe Epilepsy", The Journal of Neuroscience, Jly 15, 2002, 22(14):5797-5802
	30	PEET MALCOLM, "Eicosapentaenoic acid in the treatment of schizophrenia and depression: Rationale and preliminary double-blind clinical trial results", Prostaglandins Leukotrienes and essential fatty acids, Vol. 69, No. 6, December 2003
	31	PERSICO et al., "Reelin gene alleles and haplotypes as a factor predisposing to autistic disorder", Molecular Psychiatry (2001)6, 150-159
	32	FENG et al., "Brain lipid-binding protein (BLBP): A novel signaling system in the developing mammalian CNS", Neuron, 1994 Apr; 12(4):895-908
	33	FENG and HEINTZ, "Differentiating neurons activate transcription of the brain lipid-binding protein gene in radial glia through a novel regulatory element", Development, 1995, 121, 1719-1730
	34	International Search Report dated November 3, 2005, for PCT Application No. PCT/US2005/002177
	35	Written Opinion dated November 3, 2005, for PCT Application No. PCT/US2005/002177
	36	International Preliminary Report on Patentability dated July 24, 2006, for PCT Application No. PCT/US2005/002177

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449A/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	10/597,304
				Filing Date	July 19, 2006
				First Named Inventor	John P. Morseman
				Art Unit	1614
				Examiner Name	Jennifer M. Kim
Sheet	4	of	4	Attorney Docket Number	2997-74-PUS

	37	Supplementary European Search Report for European Application No. 05706056.8, dated February 17, 2009 (Attorney's Reference No. 2997-74-PEP)
	38	Office Action for Chinese Patent Application No. 200580008876.X, issued 9-5-08 (Attorney's Ref. No. 2997-74-PCN)

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference is considered, whether or not citation is in conformance and not considered. Include copy of this form with next communication to applicant.